Agilent Technologies said today that it has agreed to acquire privately held life science instrumentation manufacturer BioTek Instruments for $1.17 billion in cash.
With anticipated tax benefits for Agilent, the net purchase price is expected to be approximately $1.05 billion. Agilent expects the transaction to be completed in its fiscal fourth quarter, subject to regulatory approvals.
Winooski, Vermont-based BioTek designs, manufactures, and sells instruments for the life science industry, including cell imaging systems, microplate readers, washers, dispensers, automated incubators, and stackers. The company generated revenues of $162 million in 2018, and is expected to grow approximately 10 percent in 2019, Agilent noted.
Full Content: Bloomberg